Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V116 vs PNEUMOVAX 23 in Healthy Japanese Adults
NCT04665050Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Solicited Injection-site Adverse Event at 5 days, Percentage of Participants With a Solicited Systemic Adverse Event at 5 days and 1 more. Started Feb 2021; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04665050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665050.